Explore more publications!
Hawaii Health Digest
Submit Press Release

Hawaii Health Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Hawaii Health Digest.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 29, 2025

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Indeterminate GlobeNewswire
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
September 29, 2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Indeterminate GlobeNewswire
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …
September 29, 2025

NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …

Indeterminate GlobeNewswire
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
September 29, 2025

Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements

Indeterminate GlobeNewswire
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025

INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Indeterminate GlobeNewswire
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
September 29, 2025

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Indeterminate GlobeNewswire
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
September 29, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Indeterminate GlobeNewswire
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
September 29, 2025

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Indeterminate GlobeNewswire
Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results
September 29, 2025

Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Indeterminate GlobeNewswire
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Indeterminate GlobeNewswire
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Indeterminate GlobeNewswire
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Indeterminate GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
September 29, 2025

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Indeterminate GlobeNewswire
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2025

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 29, 2025

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Indeterminate GlobeNewswire
ImmuCell Announces Selection of its Next President and CEO
September 29, 2025

ImmuCell Announces Selection of its Next President and CEO

Indeterminate GlobeNewswire
Alameda Health System is recognized as one of Newsweek’s America’s Best Nursing Homes 2026
September 29, 2025

Alameda Health System is recognized as one of Newsweek’s America’s Best Nursing Homes 2026

Indeterminate GlobeNewswire
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
September 29, 2025

SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
September 29, 2025

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

Indeterminate GlobeNewswire
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
September 29, 2025

Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions